Age and Multimorbidity Predict Death Among COVID-19 Patients Results of the SARS-RAS Study of the Italian Society of Hypertension
- 1 August 2020
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Hypertension
- Vol. 76 (2), 366-372
- https://doi.org/10.1161/HYPERTENSIONAHA.120.15324
Abstract
Several factors have been proposed to explain the high death rate of the coronavirus disease 2019 (COVID-19) outbreak, including hypertension and hypertension-related treatment with Renin Angiotensin System inhibitors. Also, age and multimorbidity might be confounders. No sufficient data are available to demonstrate their independent role. We designed a cross-sectional, observational, multicenter, nationwide survey in Italy to verify whether renin-angiotensin system inhibitors are related to COVID-19 severe outcomes. We analyzed information from Italian patients diagnosed with COVID-19, admitted in 26 hospitals. One thousand five hundred ninety-one charts (male, 64.1%; 66 +/- 0.4 years) were recorded. At least 1 preexisting condition was observed in 73.4% of patients, with hypertension being the most represented (54.9%). One hundred eighty-eight deaths were recorded (11.8%; mean age, 79.6 +/- 0.9 years). In nonsurvivors, older age, hypertension, diabetes mellitus, chronic obstructive pulmonary disease, chronic kidney disease, coronary artery diseases, and heart failure were more represented than in survivors. The Charlson Comorbidity Index was significantly higher in nonsurvivors compared with survivors (4.3 +/- 0.15 versus 2.6 +/- 0.05;P<0.001). ACE (angiotensin-converting enzyme) inhibitors, diuretics, and beta-blockers were more frequently used in nonsurvivors than in survivors. After correction by multivariate analysis, only age (P=0.0001), diabetes mellitus (P=0.004), chronic obstructive pulmonary disease (P=0.011), and chronic kidney disease (P=0.004) but not hypertension predicted mortality. Charlson Comorbidity Index, which cumulates age and comorbidities, predicts mortality with an exponential increase in the odds ratio by each point of score. In the COVID-19 outbreak, mortality is predicted by age and the presence of comorbidities. Our data do not support a significant interference of hypertension and antihypertensive therapy on COVID-19 lethality.Keywords
This publication has 39 references indexed in Scilit:
- 2018 ESC/ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of HypertensionJournal Of Hypertension, 2018
- Therapeutic time window for angiotensin-(1-7) in acute lung injuryBritish Journal of Pharmacology, 2016
- A SARS-like cluster of circulating bat coronaviruses shows potential for human emergenceNature Medicine, 2015
- Blood pressure levels and control in Italy: comprehensive analysis of clinical data from 2000–2005 and 2005–2011 hypertension surveysJournal of Human Hypertension, 2015
- Human intestine luminal ACE2 and amino acid transporter expression increased by ACE-inhibitorsAmino Acids, 2014
- Angiotensin-converting enzyme 2 protects from severe acute lung failureNature, 2005
- Effect of Angiotensin-Converting Enzyme Inhibition and Angiotensin II Receptor Blockers on Cardiac Angiotensin-Converting Enzyme 2Circulation, 2005
- The Epidemiology of Severe Acute Respiratory Syndrome in the 2003 Hong Kong Epidemic: An Analysis of All 1755 PatientsAnnals of Internal Medicine, 2004
- Undertreatment of hypertension in community-dwelling older adultsJournal Of Hypertension, 1999
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987